Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Brain Biosciences, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- PFWBBNMA5LN7
- Solicitation number
- PA12-088
- Topic code
- NIMH
Research abstract
DESCRIPTION (provided by applicant): Neurodegenerative diseases, such as Alzheimer and other dementias, present significant societal and economic burden. The number of patients suffering from these disorders grows rapidly owing to the aging of the world population. Alzheimer's Association projects that the number of Americans living with Alzheimer's disease (AD) will increase from 5.4M today to 16 M in 2050. Management and treatment of brain disorders is a critical task facing the healthcare innovation system; continuing progress in this field will depend on early, high-confidence diagnosis. Amyloid imaging agents, the new promising class of Positron Emission Tomography (PET) radiopharmaceuticals, enable diagnosis of Alzheimer's pathology at the early stagesof disease. Brain Biosciences seeks to make neurological PET imaging affordable and widely available both in the clinic and in the research laboratory. To achieve this goal we aim to develop, validate, and obtain 510(k) FDA clearance for CerePET , a compact, portable, high-performance, and cost- effective, PET scanner for brain imaging. This innovative device is designed to achieve high resolution at a fraction of the cost of currently marketed whole body PET systems. CerePET applications include: (i) evaluation of amyloid burden in patients with suspected Alzheimer disease, mild cognitive impairment, and other neurodegenerative disorders, (ii) multicenter clinical trials of CNS-targeted pharmaceuticals using PET scan as a biomarker, (iii) clinical neuroscience research. During this Fast-track SBIR project, CerePET will be rigorously validated using a set of internationally recognized tests. CerePET imaging performance will be characterized per NEMA NU2-2007; the scanner will be used in a clinical study comparing amyloid burden in patients with Alzheimer's disease and healthy controls. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This application proposes to develop small-footprint, high performance Positron Emission Tomography (PET) scanneroptimized for brain imaging. This device will lower the cost and increase availability of neurological PET examinations both in the clinical and research settings.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
3 SBIR/STTR records share this UEI (2013–2015). Reported award amounts total $3,591,615. Reported amounts are not federal obligations.
Phases: Phase II, Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards